September 10, 2019
- Manual of Policies and Procedures (MAPP) 6700.9 FDA Posting of Potential Signals of Serious Risks Identified by the FDA Adverse Event Reporting System
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- Drugs@FDA Data Files (updated)
- FDA Drug Shortages
- Bupivacaine Hydrochloride Injection, USP (Updated - Currently in Shortage)
- Deferoxamine Mesylate for Injection, USP (Updated - Resolved)
- Dextrose 50% Injection (Updated - Currently in Shortage)
- Epinephrine Injection, 0.1 mg/mL (Updated - Currently in Shortage)
- Hydromorphone Hydrochloride Injection, USP (Updated - Currently in Shortage)
- Ketorolac Tromethamine Injection (Updated - Currently in Shortage)
- Latanoprost Ophthalmic Solution 0.005% (Updated - Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated - Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Updated - Currently in Shortage)
- Morphine Sulfate Injection, USP (Updated - Currently in Shortage)
- Pantoprazole Sodium for Injection (Updated - Currently in Shortage)
- Potassium Acetate Injection, USP (Updated - Currently in Shortage)
- Sodium Acetate Injection, USP (Updated - Currently in Shortage)
- Sodium Bicarbonate Injection, USP (Updated - Currently in Shortage)
- Sodium Chloride 23.4% Injection (Updated - Currently in Shortage)
- Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance
- La FDA advierte sobre la ocurrencia poco común de daños hepáticos graves con el uso de los medicamentos Mavyret, Zepatier y Vosevi contra la hepatitis C en algunos pacientes con enfermedad hepática avanzada
- National Drug Code Directory (updated)
- Wholesale Distributor and Third-Party Logistics Providers Reporting (updated)
.png)
No hay comentarios:
Publicar un comentario